Author： Doggrell Sheila A
Publisher： Informa Healthcare
ISSN： 1354-3784
Source： Expert Opinion on Investigational Drugs, Vol.13, Iss.5, 2004-05, pp. : 551-554
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Efalizumab a CLEAR winner for psoriasis
Inpharma, Vol. 1, Iss. 1479, 2005-01 ,pp. :
Access to resources
Recommend
Efalizumab's efficacy in psoriasis extends to the extremities
Inpharma, Vol. 1, Iss. 1576, 2007-01 ,pp. :
Efalizumab: durable benefits in plaque psoriasis
Inpharma, Vol. 1, Iss. 1385, 2003-01 ,pp. :
Efalizumab withdrawal: Rebound psoriasis, treated with infliximab then efalizumab: case report
Reactions Weekly, Vol. 1, Iss. 1240, 2009-01 ,pp. :
Adalimumab/efalizumab/infliximab: Psoriasis: 5 case reports
Reactions Weekly, Vol. 1, Iss. 1210, 2008-01 ,pp. :